Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases

Autor: Vincent Cottin, Luca Richeldi, Ivan Rosas, Maria Otaola, Jin Woo Song, Sara Tomassetti, Marlies Wijsenbeek, Manuela Schmitz, Carl Coeck, Susanne Stowasser, Rozsa Schlenker-Herceg, Martin Kolb, the INBUILD Trial Investigators

Publikováno v: Respiratory Research, Vol 22, Iss 1, Pp 1-9 (2021)

Abstract Background In the INBUILD trial in patients with chronic fibrosing interstitial lung diseases (ILDs) and a progressive phenotype, nintedanib reduced the rate of ILD progression with adverse events that were manageable for most patients. We i

Externí odkaz: https://doaj.org/article/d8c55232eae14e8a9db83cf8df243e12

Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials

Autor: Ulrich Costabel, Jürgen Behr, Bruno Crestani, Wibke Stansen, Rozsa Schlenker-Herceg, Susanne Stowasser, Ganesh Raghu

Publikováno v: Respiratory Research, Vol 19, Iss 1, Pp 1-9 (2018)

Abstract Background The benefits and risks of anti-acid medication in patients with idiopathic pulmonary fibrosis (IPF) remain a topic of debate. We investigated whether use of anti-acid medication at baseline was associated with differences in the n

Externí odkaz: https://doaj.org/article/8b179396648a46a89fb582afc19b0bf5

Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases

Autor: Kevin K. Brown, Yoshikazu Inoue, Kevin R. Flaherty, Fernando J. Martinez, Vincent Cottin, Francesco Bonella, Stefania Cerri, Sonye K. Danoff, Stephane Jouneau, Rainer‐Georg Goeldner, Martin Schmidt, Susanne Stowasser, Rozsa Schlenker‐Herceg, Athol U. Wells

Publikováno v: Respirology
Respirology, 2022, 27 (4), pp.294-300. ⟨10.1111/resp.14231⟩

International audience; Background and objective Demographic and clinical variables, measured at baseline or over time, have been associated with mortality in subjects with progressive fibrosing interstitial lung diseases (ILDs). We used data from th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42f11f29b919d8ce03a849a468d40931
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85125387576

Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis

Autor: Toby M. Maher, Wibke Stansen, Yoshikazu Inoue, Vincent Cottin, Kevin K. Brown, Athol U. Wells, Ganesh Raghu, Susanne Stowasser, Kevin R. Flaherty, Arata Azuma, Luca Richeldi, Rozsa Schlenker-Herceg, John T. Huggins

Publikováno v: Respiratory Medicine. 146:42-48

Background In the INPULSIS® trials, nintedanib reduced the annual rate of decline in forced vital capacity (FVC) versus placebo, consistent with slowing of disease progression. We characterised the effects of nintedanib on physiologic outcomes using

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6e13d9dac353bfa9a7cf63b987603c3
https://doi.org/10.1016/j.rmed.2018.11.012

Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease

Autor: Ulrike Schmid, Nicolaus Schwerk, Mihaela Dumistracel, Steven Cunningham, Kay Tetzlaff, Kevin R. Flaherty, Kevin K. Brown, Robin R. Deterding, David Warburton, Emmanuelle Clerisme-Beaty, Florian Voss, Gail H. Deutsch, Susanne Stowasser, Emily M. DeBoer, Lisa R. Young, Annick Clement, Matthias Griese, Daniela Verri, Rozsa Schlenker-Herceg, Marilisa Schiwek

Publikováno v: Deterding, R, Griese, M, Deutsch, G, Warburton, D, DeBoer, E, Cunningham, S, Clement, A, Schwerk, N, Flaherty, K R, Brown, K K, Voss, F, Schmid, U, Schlenker-Herceg, R, Verri, D, Dumistracel, M, Schiwek, M, Stowasser, S, Tetzlaff, K, Clerisme-Beaty, E & Young, L R 2021, ' Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease ', ERJ Open Research . https://doi.org/10.1183/23120541.00805-2020
ERJ Open Research, Vol 7, Iss 2 (2021)
ERJ Open Research
article-version (VoR) Version of Record

Childhood interstitial lung disease (chILD) comprises >200 rare respiratory disorders, with no currently approved therapies and variable prognosis. Nintedanib reduces the rate of forced vital capacity (FVC) decline in adults with progressive fibrosin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dca86d3042ae77819c9bb9e7f0b5f05d
https://www.pure.ed.ac.uk/ws/files/205704745/23120_1_.pdf